open access

Vol 87, No 2 (2019)
ORIGINAL PAPERS
Published online: 2019-04-18
Submitted: 2018-12-06
Accepted: 2019-04-07
Get Citation

Rapid oncological diagnosis of lung cancer patients — specific facility experience

Rafał Andrzej Sokołowski, Michał Rząd, Agnieszka Zaręba, Szczepan Czerniak, Karina Jahnz-Różyk
DOI: 10.5603/ARM.2019.0016
·
Pubmed: 31038720
·
Adv Respir Med 2019;87(2):96-102.

open access

Vol 87, No 2 (2019)
ORIGINAL PAPERS
Published online: 2019-04-18
Submitted: 2018-12-06
Accepted: 2019-04-07

Abstract

Introduction: In order to improve diagnosis procedure by public health service, an organizational solution called Rapid Oncological Therapy has been introduced. The introduction of this program caused criticism of the medical community, and state control authorities showed irregularities in its functioning in medical clinics. Its aim was to assess this process among lung cancer patients hospitalized in the Clinic for 9 months. Material and methods: After the analysis of imaging tests, the patients were qualified for invasive tests (bronchoscopy, EBUS). Patients with histopathological diagnosis of NSCLC were subjected to molecular diagnostics. After completing the diagnosis and establishing the final diagnosis, the patient's forfeiture was presented at the clinical meeting. Results: The analysis involved 209 patients who had a DILO card issued. 156 patients were diagnosed with lung cancer and qualified for the consulate. Among the histopathological types, NSCLC dominated — 80%. SCLC was 17% of the types. By the decision made on medical case conference, 135 patients have been qualified for casual treatment, among others 12% surgical treatment; 47% chemotherapy, 18% radiotherapy; 8% chemo-radiotherapy. An average waiting time for diagnosis process to begin, after DILO card has been issued was 16.33 (± 18.78) days, an average hospitalization and diagnosis time was 9.16 (± 6.61) days. Around 31.3 (± 14.93) days on average have passed from the start of diagnostical hospitalization until beginning of the causal treatment. Conclusions: In a multi-specialist center, it is possible to develop a care model for lung cancer patients, consistent with Rapid Oncological Diagnosis.

Abstract

Introduction: In order to improve diagnosis procedure by public health service, an organizational solution called Rapid Oncological Therapy has been introduced. The introduction of this program caused criticism of the medical community, and state control authorities showed irregularities in its functioning in medical clinics. Its aim was to assess this process among lung cancer patients hospitalized in the Clinic for 9 months. Material and methods: After the analysis of imaging tests, the patients were qualified for invasive tests (bronchoscopy, EBUS). Patients with histopathological diagnosis of NSCLC were subjected to molecular diagnostics. After completing the diagnosis and establishing the final diagnosis, the patient's forfeiture was presented at the clinical meeting. Results: The analysis involved 209 patients who had a DILO card issued. 156 patients were diagnosed with lung cancer and qualified for the consulate. Among the histopathological types, NSCLC dominated — 80%. SCLC was 17% of the types. By the decision made on medical case conference, 135 patients have been qualified for casual treatment, among others 12% surgical treatment; 47% chemotherapy, 18% radiotherapy; 8% chemo-radiotherapy. An average waiting time for diagnosis process to begin, after DILO card has been issued was 16.33 (± 18.78) days, an average hospitalization and diagnosis time was 9.16 (± 6.61) days. Around 31.3 (± 14.93) days on average have passed from the start of diagnostical hospitalization until beginning of the causal treatment. Conclusions: In a multi-specialist center, it is possible to develop a care model for lung cancer patients, consistent with Rapid Oncological Diagnosis.

Get Citation

Keywords

rapid oncological diagnosis, lung cancer, DILO card (diagnosis and oncological treatment card)

About this article
Title

Rapid oncological diagnosis of lung cancer patients — specific facility experience

Journal

Advances in Respiratory Medicine

Issue

Vol 87, No 2 (2019)

Pages

96-102

Published online

2019-04-18

DOI

10.5603/ARM.2019.0016

Pubmed

31038720

Bibliographic record

Adv Respir Med 2019;87(2):96-102.

Keywords

rapid oncological diagnosis
lung cancer
DILO card (diagnosis and oncological treatment card)

Authors

Rafał Andrzej Sokołowski
Michał Rząd
Agnieszka Zaręba
Szczepan Czerniak
Karina Jahnz-Różyk

References (19)
  1. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. GLOBOCAN 2012. http://http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (10.01.2019).
  2. World Health Organization; Global Status Report on noncommunicable diseases. Geneva, WHO 2014.
  3. Wojciechowska U., Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org.pl/raporty/ (22.02.2019 ).
  4. Ministerstwo Zdrowia. http://mz.gov.pl (22.02.2019 ).
  5. Internetowy System Aktów Prawnych. http://prawo.sejm.gov.pl/ (22.02.2019 ).
  6. Matczak M, Zalasiński T, Czarnuch M. Raport regulacyjny w sprawie oceny konstytucyjności ustawy z dnia 22 lipca 2014 r. o zmianie ustawy o świadczeniach opieki zdrowotnej finansowanych ze środków publicznych oraz niektórych innych ustaw (wprowadzającej tzw. pakiet onkologiczny i kolejkowy). https://www.nil.org.pl/ (22.02.2019).
  7. Najwyższa Izba Kontroli; Informacja o wynikach kontroli. Przygotowanie i wdrożenie pakietu onkologicznego. NIK 2017. https://www.nik.gov.pl/kontrole/P/16/057/LPO (20.02.2019).
  8. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018; 13(3): 323–358.
  9. Mapa potrzeb zdrowotnych w zakresie onkologii dla Polski. http://www.mpz.mz.gov.pl/mapy-potrzeb-zdrowotnych-w-zakresie-onkologii/ (12.12.2018).
  10. Chorostowska-Wynimko J,(red.), Strategia Walki z Rakiem Płuca ; Instytut Gruźlicy i Chorób Płuc; Polska Grupa Raka Płuca, Polską Ligą Walki z Rakiem. https://ligawalkizrakiem.pl (21.01.2019).
  11. Szybka Terapia Onkologiczna, Ministerstwo Zdrowia. http://pakietonkologiczny.gov.pl/ (11.12.2018).
  12. OnkoBarometr Fundacji Watch Health Care nr 9/1/02/2017. www.korektorzdrowia.pl (11.12.2018).
  13. Analiza czasu oczekiwania pacjentów na diagnozę i leczenie chorób nowotworowych w Polsce. http://onkologia2025.pl/ (11.12.2018 ).
  14. Gibson GJ, Loddenkemper R, Lundbäck Bo, et al. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013; 42(3): 559–563.
  15. Office on Smoking and Health (US). The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2006. Indexed in PubMed 20669524.
  16. Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J. 2016; 48(3): 889–902.
  17. Chen CY, Peng HC, Chen YY, et al. Association of environmental heavy metals exposure and lung cancer incidence and prognosis. 11.1 Lung Cancer. 2016.
  18. Stanisławek A. Karta DiLO jednym z większych osiągnięć w onkologii. https://www.mp.pl/kurier/ (12.12.2018).
  19. Wojtyła A. Pakiet onkologiczny to chybiony pomysł. https://www.mp.pl/kurier (12.12.2018).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl